Alzumab (Itolizumab) 400mg Injection is a medication used to treat severe active psoriasis, including plaque psoriasis, and psoriatic arthritis. It is a monoclonal antibody that targets the CD6 protein, which is involved in the inflammatory process.
Composition: Each vial of Alzumab contains 400mg of Itolizumab (an active pharmaceutical ingredient).
Mechanism of Action: Alzumab works by binding to the CD6 protein, which is found on the surface of T-cells. By binding to CD6, Alzumab prevents the activation of T-cells and reduces the production of pro-inflammatory cytokines. This leads to a decrease in inflammation and an improvement in symptoms of psoriasis.
Dosage: The recommended dose of Alzumab is 100-200mg administered intravenously every 4-8 weeks. The dosage may be adjusted based on individual patient response and clinical improvement.
Uses: Alzumab is used to treat:
- Severe active psoriasis, including plaque psoriasis
- Psoriatic arthritis
- Moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy
Side Effects: Common side effects of Alzumab include:
- Headache
- Fatigue
- Nasopharyngitis
- Upper respiratory tract infections
- Sinusitis
- Injection site reactions
Rare but serious side effects include:
- Hypersensitivity reactions, including anaphylaxis
- Serious infections, including sepsis
- Malignancies, including lymphoma
Recommendation: Alzumab is recommended for patients with severe active psoriasis or psoriatic arthritis who have not responded to other treatments or have not tolerated other treatments. Patients with a history of malignancy or immunosuppression should be closely monitored while taking Alzumab.
Important Note:
- Alzumab should be used under the guidance of a healthcare provider with experience in the treatment of psoriasis and psoriatic arthritis.
- Patients with a history of hypersensitivity reactions to Itolizumab or other monoclonal antibodies should not receive Alzumab.
- Alzumab may interact with other medications, such as immunosuppressants, anticoagulants, and NSAIDs. Patients should inform their healthcare provider of all medications they are taking before starting Alzumab therapy.
- Patients should be advised to report any symptoms of hypersensitivity reactions, such as rash, itching, swelling, or difficulty breathing.
Reviews
There are no reviews yet.